CEL-SCI Says FDA Places Clinical Hold On Head And Neck Cancer Study

(RTTNews) - CEL-SCI Corp. (CVM) said Monday that it has received verbal notice from the U.S. Food and Drug Administration that its Multikine (Leukocyte Interleukin Injection) Phase 3 clinical trial in advanced primary head and neck cancer has been placed on clinical hold.

As per the communication from FDA, patients currently receiving study treatments can continue to receive treatment, and patients already enrolled in the study will continue to be followed. CEL-SCI was also told to expect a formal letter from the FDA within 30 days and will work diligently with the FDA to obtain the release of the clinical hold. The study currently has about 926 patients enrolled.